Brought to you by Acorda Therapeutics®, Inc. Acorda markets AMPYRA® (dalfampridine) Extended Release Tablets, 10mg; AMPYRA is manufactured under license from Alkermes Pharma Ireland Limited (APIL), Ireland.
Please see Important Safety Information below. For full Prescribing Information, please click here. For full Medication Guide, please click here.
AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.
IMPORTANT SAFETY INFORMATION
Do not take AMPYRA if you have ever had a seizure, or have certain types of kidney problems, or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.
Take AMPYRA exactly as prescribed by your doctor.
You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50.
Your doctor may do a blood test to check how well your kidneys are working, if that is not known before you start taking AMPYRA.
AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.
AMPYRA may cause serious allergic reactions. Stop taking Ampyra and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives.
AMPYRA®, ACORDA THERAPEUTICS® and the stylized ACORDA THERAPEUTICS® logo are registered trademarks of Acorda Therapeutics, Inc. | AMPYRA® is marketed by Acorda Therapeutics, Inc. and manufactured under license from Alkermes Pharma Ireland Limited (APIL), Ireland. | The stylized path logo and the stylized Acorda logo are trademarks of Acorda Therapeutics, Inc. | © 2013 Acorda Therapeutics, Inc. All rights reserved.